anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

134,821-134,880 of 319,975

filter-aware
28
The slide highlights the composition of Valeant's business segments and justifies their attractiveness.Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
29
The slide uses a dot-matrix to visualize market presence by product type and region.Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
30
Allergan, Inc. (AGN)Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
31
The slide highlights that the durable business represents ~85% of total sales.Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
32
Allergan, Inc. (AGN)Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
33
Allergan, Inc. (AGN)Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
34
The slide uses media headlines as evidence of the financial risk associated with traditional R&D models.Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
35
The slide uses a bulleted list to define the company's R&D philosophy.Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
36
Allergan, Inc. (AGN)Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
37
Allergan, Inc. (AGN)Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
38
The slide uses a waterfall-style comparison to illustrate margin efficiency.Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
39
Allergan, Inc. (AGN)Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
40
Allergan, Inc. (AGN)Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
41
Allergan, Inc. (AGN)Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
42
The slide contains two green callout boxes containing quotes, followed by the attribution.Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
43
Allergan, Inc. (AGN)Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
44
The slide uses a direct quote to frame the company's internal culture as a strategic choice.Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
45
Allergan, Inc. (AGN)Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
46
The slide uses a waterfall-style visual to contrast cost components.Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
47
Allergan, Inc. (AGN)Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
48
The slide uses a simple numerical example to illustrate the 'valuation trap' of consolidated growth metrics.Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
49
Allergan, Inc. (AGN)Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
50
Uses a conceptual line chart to explain the 'patent cliff' impact on reported growth.Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
51
The table highlights the performance of 'Total Product Sales' across different periods.Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
52
Allergan, Inc. (AGN)Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
53
The slide contains a primary quote block and a footnote reference.Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
54
Allergan, Inc. (AGN)Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
55
The slide uses a table to show the vesting schedule of performance share units (PSUs) based on annualized Total Shareholder Return (TSR).Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
56
The slide uses the 3G Capital case study as a precedent to validate Valeant's management philosophy.Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
57
Allergan, Inc. (AGN)Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
58
Allergan, Inc. (AGN)Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
59
Allergan, Inc. (AGN)Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
60
The slide uses a visual bracket to emphasize the cumulative difference between the two metrics over the three-year period.Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
61
The slide highlights specific accounting adjustments used by Valeant to inflate earnings metrics.Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
62
The slide uses a bridge-style reconciliation table to justify non-GAAP metrics.Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
63
The slide uses a table to contrast GAAP accounting practices with the author's economic view of the company's performance.Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
64
Allergan, Inc. (AGN)Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor Loop · Cost Of Inaction1 hit
65
The slide uses a dual-axis chart to correlate share price (line) with volume (bars) and Pershing Square's specific purchase activity (dark bars).Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor Loop · Cost Of Inaction1 hit
66
This slide provides factual evidence regarding the accumulation of an economic stake and the subsequent market reaction.Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor Loop · Cost Of Inaction1 hit
67
This slide is likely part of a legal or regulatory filing (SEC) documenting market activity.Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor Loop · Cost Of Inaction1 hit
68
Allergan, Inc. (AGN)Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor Loop · Cost Of Inaction1 hit
69
Allergan, Inc. (AGN)Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor Loop · Cost Of Inaction1 hit
70
Allergan, Inc. (AGN)Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
71
Allergan, Inc. (AGN)Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
72
The slide uses a 'drill-down' visual technique to show the composition of the 'Durable' segment.Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
73
The slide highlights that the analyst's 6-8% growth estimate is a slight discount to management's own projections.Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
74
Uses red 'X' icons to emphasize the lack of comparability across four industry segments.Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
75
Allergan, Inc. (AGN)Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
76
Allergan, Inc. (AGN)Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
77
The slide uses a comparison framework to justify valuation multiples by drawing parallels to a high-performing consumer sector.Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
78
Allergan, Inc. (AGN)Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
79
The chart uses a floating bar format to show ranges for three different comparable categories.Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
80
The slide details three specific conservative assumptions regarding life-cycle management, post-patent revenue, and cost variability.Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
81
The slide outlines the assumptions (10% discount rate, 10-year life, 0-5% growth) and presents a sensitivity table for DCF multiples.Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
82
The table uses a weighted average approach based on earnings contribution to derive the base business multiple.Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
83
Allergan, Inc. (AGN)Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
84
Features logos of Danaher, Liberty Media, ABInBev, and Jarden Corporation as examples of platform businesses.Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
85
The chart uses a timeline-based annotation style to correlate M&A activity with stock performance.Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
86
The slide uses 'The Outsiders' book principles as a framework for evaluating Jarden's management success.Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit
87
This slide serves as a historical context piece for an activist investor's thesis regarding a specific executive's track record.Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 1 hit